Background: The influence of concomitant brain pathologies on the progression rate in PSP is unclear.

Objectives: To analyze the frequency and severity of copathologies and their impact on the progression in PSP.

Methods: We analyzed clinic-pathological features of 101 PSP patients. Diagnoses and stages of copathologies were established according to standardized criteria, including Alzheimer's disease-related pathology, argyrophilic grains, Lewy-related pathology, transactive response DNA-binding protein 43 pathology, fused in sarcoma pathology, cerebral amyloid angiopathy, and small vessel disease. Demographic data and major clinical milestones (frequency and latency to onset) were extracted from patients' files.

Results: Only 8% of 101 patients presented with pure PSP pathology without any copathology. Alzheimer's disease-related pathology was the most frequent (84%), followed by argyrophilic grains (58%), both occurring as single copathology or in combination with other proteinopathies or cerebrovascular disease. Lewy-related and transactive response DNA-binding protein 43 copathology occurred rarely (8% and 6%, respectively). Fused in sarcoma-positive cases were not found. While being common, copathology was mostly mild in severity, with the exception of frequently widespread argyrophilic grains. Small vessel disease was also frequent (65%). Cerebral amyloid angiopathy occurred only in the presence of Alzheimer's disease-related changes (25%). The copathologies did not have major impact on prevalence and time frame of major disease milestones.

Conclusions: In PSP, concomitant neurodegenerative proteinopathies or cerebrovascular diseases are frequent, but generally mild in severity. Our data confirmed that four repeat tau is still the most relevant target for PSP, whereas the impact of copathologies on progression rate appears to be of less importance. This is relevant information for the development of disease-modifying therapies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.28011DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease-related
12
argyrophilic grains
12
progression rate
8
disease-related pathology
8
transactive response
8
response dna-binding
8
dna-binding protein
8
cerebral amyloid
8
amyloid angiopathy
8
small vessel
8

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: The brain's ability to perform a cognitive task is a dynamic process and requires small blood vessels to dilate or constrict in real time to adjust blood flow in a region-specific manner. Cerebrovascular Reactivity (CVR) measures the ability of vessels to react to vasoactive challenges. In this work, we investigated the role of CVR as a possible biomarker in small vessel disease related vascular contributions to cognitive impairment and dementia (VCID), as part of the NINDS-funded MarkVCID study.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Clinical Memory Research Unit, Lund University, Lund, Sweden.

Background: Fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non-disease related average signal (inter-individual variability), which can reduce the precision of concentration based CSF AD biomarkers. Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.

View Article and Find Full Text PDF

Background: Sleep disorders as a contributing factor to cognitive impairment have spurred growing interest. The advent of digital technology facilitates the collection of comprehensive sleep measures in a home setting. The objective of this study is to examine the association between digital sleep measures and the Montreal Cognitive Assessment (MoCA).

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a form of dementia that impairs memory, language, and daily functioning. With disease progression, AD patients reportedly experience disturbances in their awareness of self, others, and their environment. These disturbances are associated with unfavourable clinical outcomes, which prompts critical questions about how AD patients experience the world around them.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Washington University in St. Louis, Saint Louis, MO, USA.

Background: Alzheimer disease (AD) is a chronic progressive neurodegenerative disorder that presents with cognitive dysfunction, memory loss, language difficulties, emotion dysregulation, and the eventual loss of motor function and death. Magnetic resonance imaging (MRI) shows early atrophy in the medial temporal lobes, which then spreads to the posterior temporal lobe, parietal lobe, and finally the frontal lobe with relative sparing of the sensorimotor cortex. Social disadvantage has been shown to have potentially additive impacts on aging trajectories.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!